Proteomic changes induced by effective chemopreventive ratios of n-3:n-6 fatty acids and tamoxifen against MNU-induced mammary cancer in the rat

Cancer Prevention Research

Volumn 6, Issue 9, 2013, Pages 979-988

  Skibinski, Christine G ^a   Thompson, Henry J ^b   Das, Arunangshu ^a   Manni, Andrea ^a   Bortner, James D ^a   Stanley, Anne ^a   Stanley, Bruce A ^a   El Bayoumy, Karam ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1B GLYCOPROTEIN; APOLIPOPROTEIN E; GELSOLIN; GLYCOPHORIN A; HAPTOGLOBIN; METHYLNITROSOUREA; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PROTEIN 14 3 3; TAMOXIFEN; UNCLASSIFIED DRUG; VITAMIN D BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CHEMICAL CARCINOGENESIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; FEMALE; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEOMICS; RAT; WESTERN BLOTTING;

ALKYLATING AGENTS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIET; FATTY ACIDS, OMEGA-6; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLNITROSOUREA; RATS; RATS, SPRAGUE-DAWLEY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84883759398     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0152     Document Type: Article

References (50)

1. American Cancer Society. Cancer Facts and Figures 2013. Atlanta, GA: American Cancer Society; 2013.
2. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41.
3. Calviello G, Serini S. Dietary omega-3 polyunsaturated fatty acids and cancer. New York: Springer; 2010.
4. Zhu Z, Jiang W, McGinley JN, Prokopczyk B, Richie JP Jr, El Bayoumy K, et al. Mammary gland density predicts the cancer inhibitory activity of the N-3 to N-6 ratio of dietary fat. Cancer Prev Res 2011;4:1675-85.
5. Noguchi M, Minami M, Yagasaki R, Kinoshita K, Earashi M, Kitagawa H, et al. Chemoprevention of DMBA-induced mammary carcinogenesis in rats by low-dose EPA and DHA. Br J Cancer 1997;75:348-53. (Pubitemid 27051048)
6. Yuri T, Danbara N, Tsujita-Kyutoku M, Fukunaga K, Takada H, Inoue Y, et al. Dietary docosahexaenoic acid suppresses N-methyl-N-nitro-sourea-induced mammary carcinogenesis in rats more effectively than eicosapentaenoic acid. Nutr Cancer 2003;45:211-7. (Pubitemid 37022795)
7. Signori C, El-Bayoumy K, Russo J, Thompson HJ, Richie JP, Hartman TJ, et al. Chemoprevention of breast cancer by fish oil in preclinical models: trials and tribulations. Cancer Res 2011;71:6091-6.
8. U.S. Department of Agriculture and U.S. Department of Health and Human Services. Dietary Guidelines for Americans, 2010. 7th ed. Washington DC: U.S. Government Printing Office, December 2010.
9. Manni A, Xu H, Washington S, Aliaga C, Cooper T, Richie JP Jr, et al. The impact of fish oil on the chemopreventive efficacy of tamoxifen against development of N-methyl-N-nitrosourea-induced rat mammary carcinogenesis. Cancer Prev Res 2010;3:322-30.
10. Das A, Bortner JD Jr, Aliaga CA, Baker A, Stanley A, Stanley BA, et al. Changes in proteomic profiles in different prostate lobes of male rats throughout growth and development and aging stages of the life span. Prostate 2013;73:363-75.
11. Tang WH, Shilov IV, Seymour SL. Nonlinear fitting method for determining local false discovery rates from decoy database searches. J Proteome Res 2008;7:3661-7.
12. Jiang W, Zhu Z, McGinley JN, El Bayoumy K, Manni A, Thompson HJ. Identification of a molecular signature underlying inhibition of mammary carcinoma growth by dietary N-3 fatty acids. Cancer Res 2012;72:3795-806.
13. Welsh J. Vitamin D metabolism in mammary gland and breast cancer. Mol Cell Endocrinol 2011;347:55-60.
14. Custodio A, Lopez-Farre AJ, Zamorano-Leon JJ, Mateos-Caceres PJ, Macaya C, Caldes T, et al. Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers. J Cancer Res Clin Oncol 2012;138:867-75.
15. Zeng Z, Hincapie M, Pitteri SJ, Hanash S, Schalkwijk J, Hogan JM, et al. A proteomics platform combining depletion, multi-lectin affinity chromatography (M-LAC), and isoelectric focusing to study the breast cancer proteome. Anal Chem 2011;83:4845-54.
16. Kreunin P, Zhao J, Rosser C, Urquidi V, Lubman DM, Goodison S. Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. J Proteome Res 2007;6:2631-9. (Pubitemid 47122358)
17. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, et al. 14-3-3 Sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997;1:3-11. (Pubitemid 127376388)
18. Vercoutter-Edouart AS, Lemoine J, Le Bourhis X, Louis H, Boilly B, Nurcombe V, et al. Proteomic analysis reveals that 14-3-3sigma is down-regulated in human breast cancer cells. Cancer Res 2001;61:76-80. (Pubitemid 32095703)
19. Martinez-Galan J, Torres B, Del Moral R, Munoz-Gamez JA, Martin- Oliva D, Villalobos M, et al. Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy. Cancer Biol Ther 2008;7:958-65.
20. Choi JW, Liu H, Mukherjee R, Yun JW. Downregulation of fetuin-B and zinc-alpha2-glycoprotein is linked to impaired fatty acid metabolism in liver cells. Cell Physiol Biochem 2012;30:295-306.
21. Yamamoto N, Suyama H,Yamamoto N, Ushijima N. Immunotherapy of metastatic breast cancer patients with vitamin D-binding proteinderived macrophage activating factor (GcMAF). Int J Cancer 2008;122:461-7. (Pubitemid 350234736)
22. Gomme PT, Bertolini J. Therapeutic potential of vitamin D-binding protein. Trends Biotechnol 2004;22:340-5. (Pubitemid 38887542)
23. Kisker O, Onizuka S, Becker CM, Fannon M, Flynn E, D'Amato R, et al. Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia 2003;5:32-40. (Pubitemid 36151056)
24. Kalkunte S, Brard L, Granai CO, Swamy N. Inhibition of angiogenesis by vitamin D-binding protein: characterization of anti-endothelial activity of DBP-maf. Angiogenesis 2005;8:349-60.
25. Rowling MJ, Kemmis CM, Taffany DA, Welsh J. Megalin-mediated endocytosis of vitamin D binding protein correlates with 25-hydroxycholecalciferol actions in human mammary cells. J Nutr 2006;136:2754-9. (Pubitemid 44771769)
26. Kim BK, Lee JW, Park PJ, Shin YS, Lee WY, Lee KA, et al. The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Res 2009;11:R22.
27. Anderson LN, Cotterchio M, Cole DE, Knight JA. Vitamin D-related genetic variants, interactions with vitamin D exposure, and breast cancer risk among Caucasian women in Ontario. Cancer Epidemiol Biomarkers Prev 2011;20:1708-17.
28. Asch HL, Head K, Dong Y, Natoli F, Winston JS, Connolly JL, et al. Widespread loss of gelsolin in breast cancers of humans, mice, and rats. Cancer Res 1996;56:4841-5. (Pubitemid 26374415)
29. Noske A, Denkert C, Schober H, Sers C, Zhumabayeva B, Weichert W, et al. Loss of Gelsolin expression in human ovarian carcinomas. Eur J Cancer 2005;41:461-9. (Pubitemid 40187219)
30. Kim JH, Choi YK, Kwon HJ, Yang HK, Choi JH, Kim DY. Downregulation of gelsolin and retinoic acid receptor b expression in gastric cancer tissues through histone deacetylase 1. J Gastroenterol Hepatol 2004;19:218-24.
31. Chen H, Pimienta G, Gu Y, Sun X, Hu J, Kim MS, et al. Proteomic characterization of Her2/neu-overexpressing breast cancer cells. Proteomics 2010;10:3800-10.
32. Somiari RI, Sullivan A, Russell S, Somiari S, Hu H, Jordan R, et al. High-throughput proteomic analysis of human infiltrating ductal carcinoma of the breast. Proteomics 2003;3:1863-73. (Pubitemid 37305880)
33. Winston JS, Asch HL, Zhang PJ, Edge SB, Hyland A, Asch BB. Downregulation of gelsolin correlates with the progression to breast carcinoma. Breast Cancer Res Treat 2001;65:11-21. (Pubitemid 32163495)
34. Asch HL, Winston JS, Edge SB, Stomper PC, Asch BB. Downregulation of gelsolin expression in human breast ductal carcinoma in situ with and without invasion. Breast Cancer Res Treat 1999; 55:179-88. (Pubitemid 29389580)
35. Panis C, Pizzatti L, Herrera AC, Cecchini R, Abdelhay E. Putative circulating markers of the early and advanced stages of breast cancer identified by high-resolution label-free proteomics. Cancer Lett 2013;330:57-66.
36. Calon F, Lim GP, Morihara T, Yang F, Ubeda O, Salem N Jr, et al. Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease. Eur J Neurosci 2005;22:617-26. (Pubitemid 41192272)
37. Udby L, Johnsen AH, Borregaard N. Human CRISP-3 binds serum alpha(1)B-glycoprotein across species. Biochim Biophys Acta 2010; 1800:481-5.
38. Catanese JJ, Kress LF. Isolation from opossum serum of a metalloproteinase inhibitor homologous to human alpha-1B-glycoprotein. Biochemistry 1992;31:410-8.
39. Tian M, Cui YZ, Song GH, Zong MJ, Zhou XY, Chen Y, et al. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 2008;8:241.
40. Rui Z, Jian-Guo J, Yuan-Peng T, Hai P, Bing-Gen R. Use of serological proteomic methods to find biomarkers associated with breast cancer. Proteomics 2003;3:433-9.
41. Slagsvold JE, Pettersen CH, Storvold GL, Follestad T, Krokan HE, Schonberg SA. DHA alters expression of target proteins of cancer therapy in chemotherapy resistant SW620 colon cancer cells. Nutr Cancer 2010;62:611-21.
42. Maffei M, Funicello M, Vottari T, Gamucci O, Costa M, Lisi S, et al. The obesity and in flammatory marker haptoglobin attracts monocytes via interaction with chemokine (C-C motif) receptor 2 (CCR2). BMC Biol 2009;7:87.
43. Goufman EI, Moshkovskii SA, Tikhonova OV, Lokhov PG, Zgoda VG, Serebryakova MV, et al. Two-dimensional electrophoretic proteome study of serum thermostable fraction from patients with various tumor conditions. Biochem Biokhimiia 2006;71:354-60.
44. Huang HL, Stasyk T, Morandell S, Dieplinger H, Falkensammer G, Griesmacher A, et al. Biomarker discovery in breast cancer serumusing 2-Ddifferential gel electrophoresis/MALDI-TOF/TOF and data validation by routine clinical assays. Electrophoresis 2006;27:1641-50.
45. Dowling P, Clarke C, Hennessy K, Torralbo-Lopez B, Ballot J, Crown J, et al. Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. Int J Cancer 2012;131:911-23.
46. van Winden AW, van den Broek I, Gast MC, Engwegen JY, Sparidans RW, van Dulken EJ, et al. Serum degradome markers for the detection of breast cancer. J Proteome Res 2010;9:3781-8.
47. van den Broek I, Sparidans RW, van Winden AW, Gast MC, van Dulken EJ, Schellens JH, et al. The absolute quantification of eight inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4)-derived peptides in serum from breast cancer patients. Proteomics Clin Appl 2010;4:931-9.
48. Pu XP, Iwamoto A, Nishimura H, Nagasawa S. Purification and characterization of a novel substrate for plasma kallikrein (PK-120) in human plasma. Biochim Biophys Acta 1994;1208:338-43. (Pubitemid 24331634)
49. Saadat M. Apolipoprotein E (APOE) polymorphisms and susceptibility to breast cancer: a meta-analysis. Cancer Res Treat 2012;44:121-6.
50. Opstal-van Winden AW, Krop EJ, Karedal MH, Gast MC, Lindh CH, Jeppsson MC, et al. Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study. BMC Cancer 2011;11:381.